Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Biochem Pharmacol. 2016 Jun 25;122:1–9. doi: 10.1016/j.bcp.2016.06.014

Figure 2. Signaling scheme showing some of the overlapping mechanisms behind the adaptive regulation of MITF expression following BRAF inhibitor treatment.

Figure 2

The adaptive signaling state in BRAF mutant melanoma cells can be driven through Wnt5a, TGF-β or a lineage specific program involving G-protein coupled receptor signaling and protein kinase A.